Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis

迟发性运动障碍 抗精神病药 医学 精神分裂症(面向对象编程) 内科学 精神科 运动障碍 荟萃分析 儿科 帕金森病 疾病
作者
Maren Carbon,Cheng‐Hsi Hsieh,John Michael Kane,Christoph Ulrich Correll
出处
期刊:The Journal of Clinical Psychiatry [Physicians Postgraduate Press, Inc.]
卷期号:78 (3): e264-e278 被引量:328
标识
DOI:10.4088/jcp.16r10832
摘要

OBJECTIVE: Comparison of tardive dyskinesia (TD) prevalence during contemporaneous treatment with first-generation antipsychotics (FGAs) and/or second-generation antipsychotics (SGAs). DATA SOURCES: PubMed/MEDLINE/Google Scholar search (January 1, 2000-September 30, 2015) without language restriction using (tardive dyskinesia OR tardive) AND (antipsychotic*) plus specific names of SGAs. STUDY SELECTION: Of 8,895 hits, we screened 203 full-text articles for cross-sectional, rating scale-based TD rates during SGA, FGA, or FGA+SGA treatment. Forty-one studies were used for random effects meta-analysis and meta-regression. DATA EXTRACTION: Two authors independently extracted data on overall and antipsychotic class-wise TD rates and on TD moderators. RESULTS: The global mean TD prevalence was 25.3% (95% CI = 22.7%-28.1%) across all 41 studies (N = 11,493, mean age = 42.8 years, male = 66.4%, schizophrenia-spectrum disorders = 77.1%). TD prevalence varied greatly: Rates were lower with current SGA treatment (20.7%; 95% CI = 16.6%-25.4%, N = 5,103) vs current FGA treatment (30.0%; 95% CI = 26.4%-33.8%, N = 5,062; Q = 9.17, P = .002). This difference remained significant after controlling for moderators: higher age (Z = 2.85, P = .004; number of studies = 39 ) and region (39 studies; Asia vs Europe, Z = 1.55, P = .12; Asia lower than United States, Z = 2.6, P = .009; Asia lower than other regions, Z = 2.42, P = .015). Additional moderators of TD prevalence included longer illness duration (R² = 0.15; P = .03; 21 studies) and frequency of parkinsonism (R² = 0.23, P = .017; number of studies = 19). Particularly low TD prevalence (7.2%; number of studies = 4) was found in the treatment arms with FGA-naive subjects relative to SGA-treated cohorts with likely prior FGA exposure (23.4%; P < .001; 28 studies). Lower TD prevalence of SGA relative to FGA was also confirmed in the subgroup of studies reporting on ≥ 2 antipsychotic classes/combinations; this was found for both SGAs vs FGAs (risk ratio = 0.80; 95% CI = 0.67-0.95, Z = -2.55, P = .011) and FGA + SGA vs FGAs (risk ratio = 0.80, 95% CI = 0.71-0.90, Z = -3.56, P < .001). Reports on TD severity, provided by 10 studies, were of insufficient quality for meta-analysis. CONCLUSIONS: Rating scale-based TD remains highly prevalent, with higher rates during FGA than during SGA treatment. However, TD severity was insufficiently reported to allow for interpretation of the clinical impact of identified TD cases with SGAs and FGAs. Reasons for high geographical variation warrant future research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
随意发布了新的文献求助10
1秒前
科目三的应助被fake采纳,获得10
1秒前
Hello的应助被酷酷的冬灵采纳,获得20
2秒前
2秒前
一一完成签到 ,获得积分10
2秒前
lang发布了新的文献求助10
2秒前
2秒前
Tuniverse_发布了新的文献求助10
3秒前
gxgxnn发布了新的文献求助10
3秒前
3秒前
随意发布了新的文献求助10
4秒前
随意发布了新的文献求助10
4秒前
随意发布了新的文献求助10
4秒前
5秒前
魏伯安发布了新的文献求助10
6秒前
耦23发布了新的文献求助10
7秒前
Magnolia_Yun发布了新的文献求助30
7秒前
星辰大海的应助被酷炫笑柳采纳,获得10
8秒前
six完成签到,获得积分10
9秒前
10秒前
10秒前
11秒前
华仔的应助被茉云采纳,获得10
12秒前
12秒前
个性青寒完成签到,获得积分10
13秒前
13秒前
13秒前
14秒前
15秒前
烟花的应助被sghsh采纳,获得10
15秒前
saflgf发布了新的文献求助10
15秒前
烟花的应助被XX采纳,获得10
16秒前
16秒前
17秒前
null发布了新的文献求助10
17秒前
CodeCraft的应助被想人陪的蚂蚁采纳,获得30
18秒前
万能图书馆的应助被CITY111119采纳,获得50
18秒前
大药瓶子发布了新的文献求助10
18秒前
火星上的寄凡完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640